Steven Seedhouse Analyst PerformanceBiotechnology Equity Research at Cantor FitzgeraldSteven Seedhouse is a stock analyst at Cantor Fitzgerald in the medical sector, covering 15 publicly traded companies. Over the past year, Steven Seedhouse has issued 14 stock ratings, including strong buy, buy, and hold recommendations. While full access to Steven Seedhouse's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Steven Seedhouse's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings59 Last 7 YearsBuy Recommendations79.66% 47 Buy RatingsCompanies Covered15 Unique Companies Ratings Distribution59RatingsDistribution of strong buy, buy, hold, and sell ratings by Steven Seedhouse.RatingPercentageCount Strong Buy20.3%12 ratings Buy59.3%35 ratings Hold16.9%10 ratings Sell3.4%2 ratingsOut of 59 total stock ratings issued by Steven Seedhouse at Cantor Fitzgerald, the majority (59.3%) have been Buy recommendations, followed by 20.3% Strong Buy, 16.9% Hold, and 3.4% Sell.Best & Worst CallsBest Call000.0%PRQRAug 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%IFRXMay 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ15 companiesSteven Seedhouse, an analyst at Cantor Fitzgerald, currently covers 15 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies100.0%Steven Seedhouse of Cantor Fitzgerald specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE12 companies80.0%MED - DRUGS2 companies13.3%BIOTECHNOLOGY1 company6.7% Steven Seedhouse's Ratings History at Cantor Fitzgerald Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsKRROKorro Bio3/13/2026Upgrade$11.50$23.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics3/10/2026Upgrade$79.23$123.00Strong-Buy$0.0000.00% ROIKRROKorro Bio1/28/2026Reiterated Rating$11.07Market Perform$0.0000.00% ROIMIRMMirum Pharmaceuticals12/11/2025Reiterated Rating$64.67$110.00Strong-Buy$0.0000.00% ROIKRROKorro Bio11/13/2025Downgrade$31.42Market Perform$0.0000.00% ROIATXSAstria Therapeutics11/12/2025Downgrade$12.55Neutral$0.0000.00% ROIBCRXBioCryst Pharmaceuticals10/15/2025Boost Price Target$6.66$26.00Overweight$0.0000.00% ROIETNB89BIO9/19/2025Downgrade$14.94Market Perform$0.0000.00% ROIATXSAstria Therapeutics9/17/2025Reiterated Rating$7.64$49.00Overweight$0.0000.00% ROIDNTHDianthus Therapeutics9/9/2025Reiterated Rating$33.61$63.00Outperform$0.0000.00% ROIKRROKorro Bio8/13/2025Lower Price Target$15.99$147.00Strong-Buy$0.0000.00% ROIMIRMMirum Pharmaceuticals8/7/2025Reiterated Rating$59.48Strong-Buy$0.0000.00% ROIMIRMMirum Pharmaceuticals8/7/2025Boost Price Target$53.39$82.00Strong-Buy$0.0000.00% ROIMIRMMirum Pharmaceuticals5/13/2025Boost Price Target$45.12$77.00Strong-Buy$0.0000.00% ROIIFRXInflaRx4/29/2025Initiated Coverage$1.22$10.00Overweight$0.0000.00% ROIBCRXBioCryst Pharmaceuticals4/29/2025Initiated Coverage$8.32$20.00Overweight$0.0000.00% ROIWVEWAVE Life Sciences4/29/2025Initiated Coverage$6.83$10.00Overweight$0.0000.00% ROIPHVSPharvaris4/29/2025Initiated Coverage$17.06$28.00Overweight$00.0000.00% ROIKRROKorro Bio4/28/2025Initiated Coverage$17.47$74.00Overweight$00.0000.00% ROIATXSAstria Therapeutics4/28/2025Initiated Coverage$4.96$47.00Overweight$0.0000.00% ROIVKTXViking Therapeutics4/28/2025Initiated Coverage$25.94$104.00Overweight$00.0000.00% ROIVKTXViking Therapeutics2/6/2025Boost Price Target$31.28$125.00Strong-Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
